share_log

大行评级|花旗:对中生制药开启30天上行催化观察 目标价为6.8港元

Gelonghui Finance ·  Jul 26 02:18

格隆汇7月26日|花旗发表报告指,由于生物仿制药及创新药的销售强劲增长,预计中国生物制药上半年业绩表现理想,料盈利按年增长约10%。由于生物仿制药、G-CSF及Cataplasms的销量增加,预期公司下半年业绩将有较高的能见度。该行开启对中生制药30天上行催化观察,目标价为6.8港元,评级“买入”。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment